Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2969729rdf:typepubmed:Citationlld:pubmed
pubmed-article:2969729lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:2969729lifeskim:mentionsumls-concept:C0032105lld:lifeskim
pubmed-article:2969729lifeskim:mentionsumls-concept:C0003593lld:lifeskim
pubmed-article:2969729lifeskim:mentionsumls-concept:C2255831lld:lifeskim
pubmed-article:2969729lifeskim:mentionsumls-concept:C1334043lld:lifeskim
pubmed-article:2969729lifeskim:mentionsumls-concept:C0597551lld:lifeskim
pubmed-article:2969729pubmed:issue2lld:pubmed
pubmed-article:2969729pubmed:dateCreated1988-9-2lld:pubmed
pubmed-article:2969729pubmed:abstractTextApolipoproteins B and E of the human plasma lipoproteins are known inhibitors of lymphocyte proliferation. In this report, two synthetic peptide amides, apoB3358-3372 and apoE141-155, showed a dose-dependent inhibition of both the murine mixed lymphocyte culture reaction and the anti-T3 induced proliferation of lymphocytes. Their structures and antiproliferative potencies were similar to that of the heptadecapeptide CKS-17, a consensus peptide of a highly conserved region among HTLV-I, -II and C-type human retroviral proteins. SP-9-2-amide, a peptide homologous to the amino-terminal half of CKS-17, also suppressed lymphocyte activation. In contrast, a peptide homologous to the gp41 protein of HTLV-III that is sequence related to CKS-17 (approximately 35% homology) showed little antiproliferative activity. Neurotensin, a control peptide, showed no activity. The results suggest that a basic tetrapeptide sequence common to CKS-17-amide, SP-9-2, apoB3358-3372 and apoE141-155, but not HTLV-III-amide may account, in part, for the antiproliferative activities of these peptides.lld:pubmed
pubmed-article:2969729pubmed:languageenglld:pubmed
pubmed-article:2969729pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2969729pubmed:citationSubsetIMlld:pubmed
pubmed-article:2969729pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2969729pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2969729pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2969729pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2969729pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2969729pubmed:statusMEDLINElld:pubmed
pubmed-article:2969729pubmed:monthJullld:pubmed
pubmed-article:2969729pubmed:issn0006-291Xlld:pubmed
pubmed-article:2969729pubmed:authorpubmed-author:CardinA DADlld:pubmed
pubmed-article:2969729pubmed:authorpubmed-author:KrstenanskyJ...lld:pubmed
pubmed-article:2969729pubmed:authorpubmed-author:BowlinT LTLlld:pubmed
pubmed-article:2969729pubmed:issnTypePrintlld:pubmed
pubmed-article:2969729pubmed:day29lld:pubmed
pubmed-article:2969729pubmed:volume154lld:pubmed
pubmed-article:2969729pubmed:ownerNLMlld:pubmed
pubmed-article:2969729pubmed:authorsCompleteYlld:pubmed
pubmed-article:2969729pubmed:pagination741-5lld:pubmed
pubmed-article:2969729pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:2969729pubmed:meshHeadingpubmed-meshheading:2969729-...lld:pubmed
pubmed-article:2969729pubmed:meshHeadingpubmed-meshheading:2969729-...lld:pubmed
pubmed-article:2969729pubmed:meshHeadingpubmed-meshheading:2969729-...lld:pubmed
pubmed-article:2969729pubmed:meshHeadingpubmed-meshheading:2969729-...lld:pubmed
pubmed-article:2969729pubmed:meshHeadingpubmed-meshheading:2969729-...lld:pubmed
pubmed-article:2969729pubmed:meshHeadingpubmed-meshheading:2969729-...lld:pubmed
pubmed-article:2969729pubmed:meshHeadingpubmed-meshheading:2969729-...lld:pubmed
pubmed-article:2969729pubmed:meshHeadingpubmed-meshheading:2969729-...lld:pubmed
pubmed-article:2969729pubmed:meshHeadingpubmed-meshheading:2969729-...lld:pubmed
pubmed-article:2969729pubmed:meshHeadingpubmed-meshheading:2969729-...lld:pubmed
pubmed-article:2969729pubmed:meshHeadingpubmed-meshheading:2969729-...lld:pubmed
pubmed-article:2969729pubmed:year1988lld:pubmed
pubmed-article:2969729pubmed:articleTitleInhibition of lymphocyte proliferation by synthetic peptides homologous to human plasma apolipoproteins B and E.lld:pubmed
pubmed-article:2969729pubmed:affiliationMerrell Dow Research Institute, Cincinnati, OH 45215.lld:pubmed
pubmed-article:2969729pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2969729lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2969729lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2969729lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2969729lld:pubmed